The Radioprotective Effect of Procaine and Procaine-Derived Product Gerovital H3 in Lymphocytes from Young and Aged Individuals
clinical paper · 2020
LINK
SUMMARY
Modern pharmacology paper examining procaine and Gerovital H3 in an experimental model. Cited for two things. First, the mechanism: procaine hydrolyzes to para-aminobenzoic acid and diethylaminoethanol, studied at oxidative-stress and radioprotective endpoints in models, as distinct from any demonstrated human anti-aging effect. Second, the present-day product: the paper's Methods describe commercially available Gerovital H3 as a 2% procaine hydrochloride injectable solution (with benzoic acid, potassium metabisulfite, and disodium phosphate, pH 3.3) manufactured by Zentiva (Romania) and approved by the Romanian National Agency of Medicines and Medical Devices under governmental order no. 1583/2012/01, obtained from a Romanian pharmacy, which grounds the case's statement that a procaine Gerovital H3 medicine remained commercially available and authorized in Romania. Citation metadata (authors, title, journal, year, article number, PMID, DOI) copied from Crossref and PubMed on 2026-06-03 (PMID 32685092, Oxid Med Cell Longev 2020:3580934; DOI 10.1155/2020/3580934).
NOTES
This 2020 paper in Oxidative Medicine and Cellular Longevity is the bundle’s reference for the modern, mechanism-level understanding of procaine and Gerovital H3: procaine hydrolyzes to para-aminobenzoic acid and diethylaminoethanol, and contemporary work studies oxidative-stress and radioprotective endpoints in animal models. It is cited to separate what the molecule does in laboratory models from the human anti-aging and disease claims that the clinical literature did not support.